Table 3. Anti-HER2 treatment patterns.
|
Anti-HER2 treatment after diagnosis of BM
|
||||
|---|---|---|---|---|
| Anti-HER2 treatment before diagnosis of BM | Trastuzumab alone (n=56), n (%) | Lapatinib alone (n=30), n (%) | Both agentsa (n=28), n (%) | No anti-HER2 treatment (n=166), n (%) |
| Trastuzumab alone (n=153) | 26 (9.3) | 28 (10.0) | 18 (6.4) | 81 (28.9) |
| Lapatinib alone (n=2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (0.7) |
| Both agentsb (n=21) | 5 (1.8) | 1 (0.4) | 2 (0.7) | 13 (4.6) |
| No anti-HER2 treatment (n=103) | 25 (8.9) | 1 (0.4) | 8 (2.9) | 69 (24.6) |
Abbreviation: BM=brain metastasis.
Note: Results are calculated as a percentage of the analysed population (n=280).
a
Trastuzumab and lapatinib given sequentially (78.6% n=22) or concomitantly (21.4% n=6).
b
Trastuzumab and lapatinib given sequentially (85.7% n=18) or concomitantly (14.3% n=3).